140 related articles for article (PubMed ID: 38054705)
1. Generation and Characterization of Iduronidase-Cleavable ADCs.
Jäger S; Könning D; Rasche N; Hart F; Sensbach J; Krug C; Raab-Westphal S; Richter K; Unverzagt C; Hecht S; Anderl J; Schröter C
Bioconjug Chem; 2023 Dec; 34(12):2221-2233. PubMed ID: 38054705
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
[TBL] [Abstract][Full Text] [Related]
3. Cleavable linkers in antibody-drug conjugates.
Bargh JD; Isidro-Llobet A; Parker JS; Spring DR
Chem Soc Rev; 2019 Aug; 48(16):4361-4374. PubMed ID: 31294429
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.
Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R
Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629
[TBL] [Abstract][Full Text] [Related]
5. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
[TBL] [Abstract][Full Text] [Related]
6. An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.
Ha SYY; Anami Y; Yamazaki CM; Xiong W; Haase CM; Olson SD; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
Mol Cancer Ther; 2022 Sep; 21(9):1449-1461. PubMed ID: 35793453
[TBL] [Abstract][Full Text] [Related]
7. Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody-Drug Conjugates.
Schmitt S; Machui P; Mai I; Herterich S; Wunder S; Cyprys P; Gerlach M; Ochtrop P; Hackenberger CPR; Schumacher D; Helma J; Vogl AM; Kasper MA
Mol Cancer Ther; 2024 Feb; 23(2):199-211. PubMed ID: 37828728
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
9. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
10. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
11. Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
Balamkundu S; Liu CF
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002080
[TBL] [Abstract][Full Text] [Related]
12. Effect of attachment site on stability of cleavable antibody drug conjugates.
Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Elgersma RC; Coumans RG; Huijbregts T; Menge WM; Joosten JA; Spijker HJ; de Groot FM; van der Lee MM; Ubink R; van den Dobbelsteen DJ; Egging DF; Dokter WH; Verheijden GF; Lemmens JM; Timmers CM; Beusker PH
Mol Pharm; 2015 Jun; 12(6):1813-35. PubMed ID: 25635711
[TBL] [Abstract][Full Text] [Related]
14. Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies.
Valsasina B; Orsini P; Caruso M; Albanese C; Ciavolella A; Cucchi U; Fraietta I; Melillo N; Fiorentini F; Rizzi S; Salsa M; Isacchi A; Gasparri F
Mol Cancer Ther; 2023 Dec; 22(12):1465-1478. PubMed ID: 37722716
[TBL] [Abstract][Full Text] [Related]
15. Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.
Miller JT; Vitro CN; Fang S; Benjamin SR; Tumey LN
Bioconjug Chem; 2021 Apr; 32(4):842-858. PubMed ID: 33788548
[TBL] [Abstract][Full Text] [Related]
16. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads.
Nakada T; Masuda T; Naito H; Yoshida M; Ashida S; Morita K; Miyazaki H; Kasuya Y; Ogitani Y; Yamaguchi J; Abe Y; Honda T
Bioorg Med Chem Lett; 2016 Mar; 26(6):1542-1545. PubMed ID: 26898815
[TBL] [Abstract][Full Text] [Related]
17. Rapid, High-Yielding Solid-Phase Synthesis of Cathepsin-B Cleavable Linkers for Targeted Cancer Therapeutics.
Pryyma A; Gunasekera S; Lewin J; Perrin DM
Bioconjug Chem; 2020 Dec; 31(12):2685-2690. PubMed ID: 33274932
[TBL] [Abstract][Full Text] [Related]
18. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
19. Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.
Dokter W; Ubink R; van der Lee M; van der Vleuten M; van Achterberg T; Jacobs D; Loosveld E; van den Dobbelsteen D; Egging D; Mattaar E; Groothuis P; Beusker P; Coumans R; Elgersma R; Menge W; Joosten J; Spijker H; Huijbregts T; de Groot V; Eppink M; de Roo G; Verheijden G; Timmers M
Mol Cancer Ther; 2014 Nov; 13(11):2618-29. PubMed ID: 25189543
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity.
Wei B; Gunzner-Toste J; Yao H; Wang T; Wang J; Xu Z; Chen J; Wai J; Nonomiya J; Tsai SP; Chuh J; Kozak KR; Liu Y; Yu SF; Lau J; Li G; Phillips GD; Leipold D; Kamath A; Su D; Xu K; Eigenbrot C; Steinbacher S; Ohri R; Raab H; Staben LR; Zhao G; Flygare JA; Pillow TH; Verma V; Masterson LA; Howard PW; Safina B
J Med Chem; 2018 Feb; 61(3):989-1000. PubMed ID: 29227683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]